Marisa Wexler, MS, senior science writer —

Target enrollment of approximately 100 participants has been reached in a Phase 3 clinical trial evaluating the investigational oral therapy diazoxide choline controlled-release (DCCR) for reducing excessive appetite in people with Prader-Willi syndrome (PWS), Soleno Therapeutics has announced. Additional patients who are already scheduled to be screened…

Medix has submitted a new drug application to the Mexican food and drug administration — Comisión Federal para la Protección contra Riesgos Sanitarios, or COFEPRIS — seeking approval of tesofensine for the treatment of obesity. Tesofensine is one of two compounds that make up Tesomet, which Saniona…

Caregivers of young children with Prader-Willi syndrome (PWS) report low quality of life, highlighting the need for additional support systems for these families, a new Chinese study has found. The findings also indicate that caregivers of PWS children with poor social skills or other symptoms such as obesity or…

Prader-Willi syndrome (PWS) has been given its own unique code by the National Center for Health Statistics (NCHS), which will make it easier to track accurate data on medical care and clinical outcomes of people with the disease. The NCHS is responsible for assigning different diseases with ICD-10…

Results of a Phase 2 clinical trial testing diazoxide chloride controlled release (DCCR) in people with Prader-Willi syndrome (PWS) showed the investigational therapy can address some unmet needs in this patient population — namely hyperphagia, or excessive appetite, and aggressive behavior. The data were published in the journal …

There is a wide range of long-term testicular function and cell-level appearance in males with Prader-Willi syndrome (PWS), a new study shows. The study, “Gonadal function and testicular histology in males with Prader‐Willi syndrome,” was published in the journal Endocrinology, Diabetes, & Metabolism. It is quite common…

A new study suggests that people with Prader-Willi syndrome (PWS) who are treated with growth hormone as children do not have growth hormone deficiency as young adults. The study, “Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome,” was published in the…

Infants with Prader-Willi syndrome can show abnormalities in motor and verbal development within the first six months of life, a case report highlights. Better understanding and recognition of these early developmental manifestations may aid in earlier diagnosis and care during the first weeks of life. The case was described in…